Med · 2024 · 42 citations · 44 references
MedicineOncologyRadiation OncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationRadiation TherapyTargeted TherapyImmune Checkpoint Inhibitor TherapyPhase Ii InvestigationRadiation-enhanced ImmunotherapyRadiotherapy Dose EscalationSmall Cell Lung Cancer ImmunotherapySmall Cell Lung Cancer PalliationSmall Cell Lung Cancer TherapySmall Cell Lung Cancer Treatment
Background Immune checkpoint inhibitors (ICIs) provide modest but unsatisfactory benefits for extensive-stage small cell lung cancer (ES-SCLC). Developing strategies for treating ES-SCLC is critical. Methods We preliminarily explored the outcomes of salvage low-dose radiotherapy (LDRT) plus ICI on refractory SCLC patients. Next, we evaluated the combinational efficacy in murine SCLC. The tumor immune microenvironment (TIME) was analyzed for mechanistic study. Subsequently, we conducted a multicenter, prospective phase II trial that administered concurrent thoracic LDRT plus chemoimmunotherapy to treatment-naive ES-SCLC patients (MATCH trial, NCT04622228). The primary endpoint was confirmed objective response rate (ORR), and the key secondary endpoints included progression-free survival (PFS) and safety. Findings Fifteen refractory SCLC patients treated with LDRT plus ICI were retrospectively reviewed. The ORR was 73.3% (95% confidence interval [CI], 44.9–92.2). We identified a specific dose of LDRT (15 Gy/5 fractions) that exhibited growth retardation and improved survival in murine SCLC when combined with ICIs. This combination recruited a special T cell population, TCF1 + PD-1 + CD8 + stem-like T cells, from tumor-draining lymph nodes into the TIME. The MATCH trial showed a confirmed ORR of 87.5% (95% CI, 75.9–94.8). The median PFS was 6.9 months (95% CI, 5.4–9.3). Conclusions These findings verified that LDRT plus chemoimmunotherapy was safe, feasible, and effective for ES-SCLC, warranting further investigation. Funding This research was funded by West China Hospital (no. ZYJC21003), the National Natural Science Foundation of China (no. 82073336), and the MATCH trial was fully funded by Roche (China) Holding Ltd. (RCHL) and Shanghai Roche Pharmaceuticals Ltd. (SRPL).
44
Comprehensive genomic profiles of small cell lung cancer
Julie George, Jing Lim, Se Jin Jang et al. · Nature · 2015 · 2.4K citations · Full text
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations
Medicine, Oncology, Pharmacology +14
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im, Masao Hashimoto, Michael Y. Gerner et al. · Nature · 2016 · 2.1K citations · Full text